Please select the option that best describes you:
Topics:
Medical Oncology
Would you use neratinib in a very-high risk Her-2 positive breast cancer patient who is ER-?
Answer from: Medical Oncologist at Community Practice
ExteNET trial of neratinib, given for one year after completion of adjuvant trastuzumab, showed a small improvement in DFS. No OS benefit. HR-positive patients derived most of this small DFS benefit. I don’t think HR-negative patients will benefit at all. But for patients who ar...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
No
Answer from: Medical Oncologist at Academic Institution
Additionally, ExteNET was conducted pre-KATHERINE. Hopefully a high-risk patient with HR-HER2+ disease would have gotten NAC, and then given the substantial benefit from TDM-1, received this if there was residual disease.